benazepril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
angiotensin-converting enzyme inhibitors	299	86541-75-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: benazepril cibacen benazepril hydrochloride benazepril HCl	prodrug of benazeprilat inhibit angiotensin-converting enzyme (ACE) and results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion Molecular weight: 424.50 Formula: C24H28N2O5 CLOGP: 1.82 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 95.94 ALOGS: -4.61 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

benazepril
cibacen
benazepril hydrochloride
benazepril HCl

prodrug of benazeprilat inhibit angiotensin-converting enzyme (ACE) and results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion

Molecular weight: 424.50
Formula: C24H28N2O5
CLOGP: 1.82
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 95.94
ALOGS: -4.61
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
7.50	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	78 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.13 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	18 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
June 25, 1991	FDA	US PHARMS HOLDINGS I

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angioedema	137.02	12.83	111	17686	47854	63423371
Cerebrovascular accident	127.18	12.83	154	17643	107870	63363355
Coronary artery disease	116.63	12.83	86	17711	32291	63438934
Myocardial infarction	115.29	12.83	141	17656	99752	63371473
Cardiac failure congestive	109.14	12.83	132	17665	92301	63378924
Off label use	69.18	12.83	53	17744	674409	62796816
Drug ineffective	55.61	12.83	133	17664	1044632	62426593
Maternal exposure during pregnancy	44.21	12.83	5	17792	220057	63251168
Contraindicated product administered	43.59	12.83	5	17792	217643	63253582
Transient ischaemic attack	43.02	12.83	53	17744	37700	63433525
Drug intolerance	42.00	12.83	17	17780	308644	63162581
Chest pain	41.52	12.83	144	17653	215815	63255410
Treatment failure	38.81	12.83	5	17792	199038	63272187
Dizziness	38.21	12.83	228	17569	429697	63041528
Blood pressure inadequately controlled	37.34	12.83	21	17776	4957	63466268
Renal failure	35.46	12.83	92	17705	117560	63353665
Swollen tongue	35.13	12.83	46	17751	34754	63436471
Systemic lupus erythematosus	34.71	12.83	8	17789	208910	63262315
Infusion related reaction	34.25	12.83	13	17784	245508	63225717
Glossodynia	33.67	12.83	5	17792	178871	63292354
Hand deformity	33.64	12.83	3	17794	159454	63311771
Mitral valve incompetence	33.50	12.83	34	17763	19560	63451665
Vasodilatation	32.28	12.83	15	17782	2380	63468845
Carotid artery stenosis	31.35	12.83	19	17778	5151	63466074
Product complaint	31.08	12.83	27	17770	12782	63458443
Oropharyngeal swelling	30.53	12.83	11	17786	910	63470315
Angina unstable	30.50	12.83	21	17776	7074	63464151
Oedema peripheral	30.22	12.83	119	17678	189392	63281833
Arteriosclerosis	30.21	12.83	24	17773	10042	63461183
Rhabdomyolysis	29.63	12.83	48	17749	43903	63427322
Renal tubular atrophy	28.50	12.83	10	17787	766	63470459
Completed suicide	26.98	12.83	96	17701	145577	63325648
Exposure during pregnancy	25.74	12.83	6	17791	155541	63315684
Wound	25.66	12.83	7	17790	163256	63307969
Nephrosclerosis	25.52	12.83	10	17787	1044	63470181
Emotional distress	25.36	12.83	38	17759	32511	63438714
Cardiovascular disorder	24.90	12.83	23	17774	11789	63459436
Cardiac disorder	24.59	12.83	48	17749	50768	63420457
Kounis syndrome	23.83	12.83	11	17786	1719	63469506
Renal injury	23.11	12.83	20	17777	9419	63461806
Tricuspid valve incompetence	22.53	12.83	24	17773	14597	63456628
Pericarditis	21.92	12.83	5	17792	131574	63339651
Arteriosclerosis coronary artery	21.02	12.83	18	17779	8355	63462870
Dehydration	20.84	12.83	100	17697	173254	63297971
Palpitations	20.60	12.83	74	17723	112696	63358529
Blood pressure increased	20.58	12.83	95	17702	161967	63309258
Depression	20.56	12.83	109	17688	196383	63274842
Gastrointestinal haemorrhage	20.00	12.83	59	17738	81117	63390108
Kidney fibrosis	19.96	12.83	10	17787	1871	63469354
Fear	19.37	12.83	23	17774	15743	63455482
Reaction to excipient	19.20	12.83	9	17788	1455	63469770
Swelling face	18.46	12.83	49	17748	63426	63407799
Product use issue	18.19	12.83	21	17776	220499	63250726
Hyperdynamic left ventricle	17.87	12.83	5	17792	181	63471044
Joint swelling	17.85	12.83	41	17756	327625	63143600
Gastrooesophageal reflux disease	17.67	12.83	63	17734	95576	63375649
Coronary artery occlusion	17.36	12.83	16	17781	8175	63463050
C-reactive protein increased	17.02	12.83	3	17794	94704	63376521
Keratoacanthoma	16.88	12.83	6	17791	477	63470748
Asthenia	15.97	12.83	171	17626	383433	63087792
Injury	15.96	12.83	51	17746	73196	63398029
Hyperlipidaemia	15.46	12.83	23	17774	19548	63451677
Tendon rupture	15.38	12.83	15	17782	8224	63463001
Blood urea increased	15.37	12.83	27	17770	26352	63444873
Blood glucose increased	15.33	12.83	55	17742	83701	63387524
Therapeutic product effect decreased	15.29	12.83	19	17778	193168	63278057
Peripheral vascular disorder	15.21	12.83	13	17784	6022	63465203
Vasoplegia syndrome	15.05	12.83	8	17789	1691	63469534
Discomfort	14.84	12.83	15	17782	167359	63303866
Alopecia	14.80	12.83	47	17750	337489	63133736
Cardiomegaly	14.35	12.83	21	17776	17593	63453632
Laryngeal pain	14.09	12.83	11	17786	4487	63466738
Mental status changes	14.07	12.83	33	17764	39566	63431659
Myalgia	13.79	12.83	79	17718	146450	63324775
Hiatus hernia	13.76	12.83	23	17774	21571	63449654
Anxiety	13.64	12.83	106	17691	217435	63253790
Pyrexia	13.53	12.83	77	17720	470401	63000824
Haemorrhoids	13.34	12.83	23	17774	22127	63449098
Intestinal ischaemia	12.84	12.83	13	17784	7455	63463770
Rheumatoid arthritis	12.84	12.83	33	17764	253786	63217439

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angioedema	197.49	13.20	145	14110	37229	34905447
Myocardial infarction	127.14	13.20	198	14057	120887	34821789
Coronary artery disease	107.93	13.20	115	14140	48190	34894486
Cardiac failure congestive	73.47	13.20	126	14129	83144	34859532
Cerebrovascular accident	70.49	13.20	125	14130	84686	34857990
Off label use	63.90	13.20	47	14208	419477	34523199
Oropharyngeal oedema	34.28	13.20	8	14247	92	34942584
Injury	33.89	13.20	42	14213	20645	34922031
Shock	31.71	13.20	44	14211	24135	34918541
Distributive shock	29.58	13.20	13	14242	1241	34941435
Swollen tongue	29.48	13.20	33	14222	14572	34928104
Chest pain	27.20	13.20	113	14142	126649	34816027
Emotional distress	27.05	13.20	32	14223	14994	34927682
Product complaint	26.95	13.20	21	14234	5869	34936807
Blood glucose increased	26.33	13.20	73	14182	66645	34876031
Nodular rash	23.37	13.20	6	14249	105	34942571
Lymphomatoid papulosis	19.70	13.20	6	14249	200	34942476
Neutropenia	19.62	13.20	21	14234	156757	34785919
Asthenia	19.31	13.20	168	14087	245083	34697593
Tongue oedema	18.96	13.20	13	14242	2984	34939692
Carotid artery stenosis	18.96	13.20	16	14239	5003	34937673
Blood pressure inadequately controlled	18.01	13.20	12	14243	2628	34940048
Depression	17.36	13.20	82	14173	97016	34845660
Blood gases abnormal	16.89	13.20	6	14249	326	34942350
Pancreatitis	16.79	13.20	44	14211	38847	34903829
Acute myocardial infarction	16.66	13.20	54	14201	53665	34889011
Angina unstable	16.48	13.20	22	14233	11631	34931045
General physical health deterioration	16.24	13.20	17	14238	128252	34814424
Cardiovascular disorder	15.80	13.20	20	14235	10036	34932640
Anxiety	15.66	13.20	81	14174	99347	34843329
Nephrogenic systemic fibrosis	15.61	13.20	13	14242	3992	34938684
Hyperlipidaemia	15.51	13.20	24	14231	14505	34928171
Fear	15.15	13.20	20	14235	10456	34932220
Pharyngeal oedema	14.55	13.20	15	14240	6032	34936644
Drug interaction	14.26	13.20	46	14209	225900	34716776
Lacunar infarction	14.10	13.20	11	14244	3079	34939597
Dizziness	13.85	13.20	143	14112	218378	34724298
Type 2 diabetes mellitus	13.76	13.20	24	14231	16008	34926668
Lip swelling	13.71	13.20	24	14231	16056	34926620
Product use in unapproved indication	13.33	13.20	17	14238	117482	34825194

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angioedema	287.48	12.01	218	24988	75817	79643365
Myocardial infarction	252.99	12.01	301	24905	183828	79535354
Coronary artery disease	243.67	12.01	186	25020	65288	79653894
Cerebrovascular accident	192.31	12.01	241	24965	155051	79564131
Cardiac failure congestive	159.00	12.01	210	24996	142192	79576990
Off label use	112.07	12.01	75	25131	907140	78812042
Chest pain	52.53	12.01	202	25004	282102	79437080
Transient ischaemic attack	51.59	12.01	73	25133	52622	79666560
Emotional distress	50.91	12.01	63	25143	39906	79679276
Angina unstable	50.80	12.01	42	25164	16485	79702697
Carotid artery stenosis	44.27	12.01	30	25176	8728	79710454
Product complaint	43.29	12.01	35	25171	13314	79705868
Swollen tongue	43.20	12.01	60	25146	42510	79676672
Drug intolerance	41.14	12.01	16	25190	264103	79455079
Cardiac disorder	40.81	12.01	74	25132	65683	79653499
Drug ineffective	40.04	12.01	191	25015	1080722	78638460
Cardiovascular disorder	39.83	12.01	38	25168	17987	79701195
Blood pressure inadequately controlled	38.18	12.01	24	25182	6153	79713029
Shock	37.80	12.01	57	25149	43491	79675691
Renal failure	37.50	12.01	144	25062	200824	79518358
Injury	36.89	12.01	78	25128	77418	79641764
Drug abuse	34.81	12.01	5	25201	162686	79556496
Arteriosclerosis	33.93	12.01	35	25171	18192	79700990
Acute myocardial infarction	33.77	12.01	75	25131	76961	79642221
Contraindicated product administered	33.34	12.01	5	25201	157533	79561649
Mitral valve incompetence	33.17	12.01	43	25163	28522	79690660
Treatment failure	32.65	12.01	7	25199	170479	79548703
Depression	31.58	12.01	144	25062	216646	79502536
Fear	30.18	12.01	36	25170	21950	79697232
Neutropenia	30.04	12.01	28	25178	287682	79431500
Hyperlipidaemia	29.86	12.01	39	25167	26054	79693128
Infusion related reaction	29.69	12.01	18	25188	230219	79488963
Dizziness	28.78	12.01	273	24933	526168	79193014
Peripheral vascular disorder	28.06	12.01	22	25184	8008	79711174
Arteriosclerosis coronary artery	27.52	12.01	31	25175	17785	79701397
Maternal exposure during pregnancy	27.41	12.01	5	25201	136533	79582649
Vasodilatation	26.50	12.01	15	25191	3176	79716006
Blood pressure increased	25.47	12.01	133	25073	211227	79507955
Renal injury	25.38	12.01	29	25177	16898	79702284
Oropharyngeal oedema	24.45	12.01	8	25198	438	79718744
Pyrexia	24.41	12.01	121	25085	678588	79040594
Tongue oedema	23.80	12.01	19	25187	7098	79712084
Tricuspid valve incompetence	23.39	12.01	30	25176	19682	79699500
Distributive shock	23.32	12.01	13	25193	2674	79716508
C-reactive protein increased	23.31	12.01	6	25200	129021	79590161
Anxiety	23.14	12.01	146	25060	248366	79470816
Blood glucose increased	22.77	12.01	84	25122	114891	79604291
Lacunar infarction	22.29	12.01	17	25189	5940	79713242
Ventricular hypertrophy	22.09	12.01	18	25188	6920	79712262
Rheumatoid arthritis	22.09	12.01	20	25186	208450	79510732
Nephrosclerosis	21.98	12.01	11	25195	1819	79717363
Exposure during pregnancy	21.89	12.01	3	25203	101129	79618053
Asthenia	21.65	12.01	252	24954	511437	79207745
Systemic lupus erythematosus	21.19	12.01	6	25200	121143	79598039
Hyperdynamic left ventricle	21.17	12.01	7	25199	396	79718786
Palpitations	20.62	12.01	87	25119	126523	79592659
Pericarditis	20.53	12.01	4	25202	104232	79614950
Completed suicide	20.22	12.01	140	25066	245627	79473555
Product use in unapproved indication	20.08	12.01	30	25176	250329	79468853
Anhedonia	19.80	12.01	24	25182	14874	79704308
Laryngeal pain	19.76	12.01	16	25190	6098	79713084
Vasoplegia syndrome	19.71	12.01	13	25193	3617	79715565
Rhabdomyolysis	19.30	12.01	74	25132	103057	79616125
Coronary artery occlusion	19.27	12.01	24	25182	15291	79703891
Renal tubular atrophy	18.95	12.01	10	25196	1846	79717336
Oropharyngeal swelling	18.93	12.01	9	25197	1331	79717851
Unevaluable event	18.85	12.01	49	25157	55536	79663646
Myocardial ischaemia	18.81	12.01	31	25175	25488	79693694
Nodular rash	18.58	12.01	6	25200	315	79718867
Joint swelling	18.31	12.01	40	25166	288606	79430576
Wound	18.14	12.01	7	25199	116172	79603010
Cardiomegaly	18.08	12.01	31	25175	26321	79692861
Lymphomatoid papulosis	18.02	12.01	6	25200	347	79718835
Kounis syndrome	17.77	12.01	13	25193	4269	79714913
Oedema peripheral	17.50	12.01	138	25068	252150	79467032
Reaction to excipient	17.48	12.01	9	25197	1580	79717602
Febrile neutropenia	17.28	12.01	29	25177	230970	79488212
Gastrointestinal haemorrhage	17.13	12.01	92	25114	147627	79571555
Atrial fibrillation	17.03	12.01	114	25092	197772	79521410
Pancreatitis	16.99	12.01	54	25152	68521	79650661
Gastritis	16.99	12.01	43	25163	47950	79671232
Pancytopenia	16.28	12.01	17	25189	165728	79553454
Musculoskeletal stiffness	16.04	12.01	19	25187	174989	79544193
Product use issue	16.01	12.01	26	25180	209796	79509386
Hypertensive heart disease	15.73	12.01	12	25194	4194	79714988
Gastrooesophageal reflux disease	15.72	12.01	70	25136	104176	79615006
Therapeutic product effect incomplete	15.72	12.01	13	25193	141632	79577550
General physical health deterioration	15.20	12.01	41	25165	275197	79443985
Ischaemic cardiomyopathy	14.72	12.01	15	25191	7680	79711502
Blood urea increased	14.52	12.01	41	25165	48749	79670433
Cerebral infarction	14.21	12.01	39	25167	45637	79673545
Swelling face	14.07	12.01	52	25154	71160	79648022
Drug interaction	13.78	12.01	76	25130	415107	79304075
Pharyngeal oedema	13.69	12.01	21	25185	16251	79702931
Tendon rupture	13.68	12.01	18	25188	12108	79707074
Hypotension	13.65	12.01	205	25001	440112	79279070
Glossodynia	13.42	12.01	8	25198	103329	79615853
Loss of personal independence in daily activities	13.24	12.01	8	25198	102572	79616610
Electrocardiogram QT prolonged	13.22	12.01	6	25200	90380	79628802
Kidney fibrosis	13.04	12.01	10	25196	3525	79715657
Neck injury	12.82	12.01	9	25197	2772	79716410
Coronary artery surgery	12.75	12.01	4	25202	191	79718991
Dehydration	12.68	12.01	127	25079	248060	79471122
Carotid artery disease	12.03	12.01	8	25198	2256	79716926

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C09AA07	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, PLAIN ACE inhibitors, plain
ATC	C09BA07	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and diuretics
ATC	C09BB13	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and calcium channel blockers
FDA MoA	N0000000181	Angiotensin-converting Enzyme Inhibitors
FDA EPC	N0000175562	Angiotensin Converting Enzyme Inhibitor
CHEBI has role	CHEBI:35457	ACE inhibitor
CHEBI has role	CHEBI:50266	Prodrugs
MeSH PA	D000806	Angiotensin-Converting Enzyme Inhibitors
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011480	Protease Inhibitors
FDA PE	N0000178477	Decreased Blood Pressure

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Chronic heart failure	off-label use	48447003
Atrial fibrillation	off-label use	49436004	DOID:0060224
Diabetic renal disease	off-label use	127013003
Acute scleroderma renal crisis	off-label use	236503001
Diastolic heart failure	off-label use	418304008	DOID:9775
Hypertension due to Scleroderma	off-label use
Nondiabetic Proteinuric Nephropathy	off-label use
Anuria	contraindication	2472002	DOID:2983
Hypercholesterolemia	contraindication	13644009
Hyperkalemia	contraindication	14140009
Jaundice	contraindication	18165001
Secondary angle-closure glaucoma	contraindication	21571006
Hypovolemia	contraindication	28560003
Dehydration	contraindication	34095006
Hyperuricemia	contraindication	35885006	DOID:1920
Angioedema	contraindication	41291007	DOID:1558
Hypokalemia	contraindication	43339004
Low blood pressure	contraindication	45007003
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Sympathectomy	contraindication	57071006
Hepatic failure	contraindication	59927004
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Hypochloremic alkalosis	contraindication	70134007
Hepatic coma	contraindication	72836002	DOID:12550
Diabetes mellitus	contraindication	73211009	DOID:9351
Chronic idiopathic constipation	contraindication	82934008
Hereditary angioneurotic edema	contraindication	82966003	DOID:14735
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Disorder of connective tissue	contraindication	105969002	DOID:65
Liver function tests abnormal	contraindication	166603001
Hypomagnesemia	contraindication	190855004
Acute pancreatitis	contraindication	197456007	DOID:2913
Disease of liver	contraindication	235856003	DOID:409
Neonatal hyperbilirubinemia	contraindication	281610001
Pregnancy, function	contraindication	289908002
Renal artery stenosis	contraindication	302233006
Neutropenic disorder	contraindication	303011007	DOID:1227
Bone marrow depression	contraindication	307762000
Azotemia	contraindication	445009001
Intestinal Angioedema	contraindication
Head and Neck Angioedema	contraindication
Hemodialysis with High-Flux Membrane	contraindication
Severe Aortic Valve Stenosis	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

Product	Applicant	Ingredients
Cardalis	Ceva Sante Animale	2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.9	acidic
pKa2	5.34	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Angiotensin-converting enzyme	Enzyme	P12821	ACE_HUMAN	INHIBITOR	IC50	6.51	WOMBAT-PK	CHEMBL
Angiotensin-converting enzyme	Enzyme		ACE_RABIT		IC50	8.70	CHEMBL
Angiotensin-converting enzyme	Enzyme		ACE_RAT		IC50	8.77	CHEMBL

External reference:

ID	Source
4020817	VUID
N0000148336	NUI
D00620	KEGG_DRUG
86541-74-4	SECONDARY_CAS_RN
1546196	RXNORM
C0053091	UMLSCUI
CHEBI:3011	CHEBI
CHEBI:88200	CHEBI
CHEMBL838	ChEMBL_ID
CHEMBL1694	ChEMBL_ID
DB00542	DRUGBANK_ID
C044946	MESH_SUPPLEMENTAL_RECORD_UI
5362124	PUBCHEM_CID
6374	IUPHAR_LIGAND_ID
C052133	MESH_SUPPLEMENTAL_RECORD_UI
6129	INN_ID
UDM7Q7QWP8	UNII
DB14125	DRUGBANK_ID
1267	MMSL
4251	MMSL
48720	MMSL
d00730	MMSL
108572003	SNOMEDCT_US
108573008	SNOMEDCT_US
372511001	SNOMEDCT_US
C0105523	UMLSCUI
CHEMBL1192519	ChEMBL_ID
4020025	VANDF
4020817	VANDF
6128	INN_ID
86541-78-8	SECONDARY_CAS_RN
5463984	PUBCHEM_CID
6375	IUPHAR_LIGAND_ID
JRM708L703	UNII
003597	NDDF
003598	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0364	CAPSULE	20 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0364	CAPSULE	20 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0364	CAPSULE	20 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0379	CAPSULE	40 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0379	CAPSULE	40 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0379	CAPSULE	40 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0405	CAPSULE	10 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0405	CAPSULE	10 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0405	CAPSULE	10 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0406	CAPSULE	20 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0406	CAPSULE	20 mg	ORAL	NDA	31 sections
Lotrel	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0406	CAPSULE	20 mg	ORAL	NDA	31 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0211	TABLET, FILM COATED	20 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0211	TABLET, FILM COATED	20 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0211	TABLET, FILM COATED	20 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0211	TABLET, FILM COATED	20 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0236	TABLET, FILM COATED	5 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0236	TABLET, FILM COATED	5 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0236	TABLET, FILM COATED	5 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0236	TABLET, FILM COATED	5 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0277	TABLET, FILM COATED	20 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0277	TABLET, FILM COATED	20 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0277	TABLET, FILM COATED	20 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0277	TABLET, FILM COATED	20 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0325	TABLET, FILM COATED	10 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0325	TABLET, FILM COATED	10 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0325	TABLET, FILM COATED	10 mg	ORAL	ANDA	22 sections
Benazepril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0325	TABLET, FILM COATED	10 mg	ORAL	ANDA	22 sections
benazepril hydrochloride and hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0574-0227	TABLET	10 mg	ORAL	NDA authorized generic	23 sections
benazepril hydrochloride and hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0574-0227	TABLET	10 mg	ORAL	NDA authorized generic	23 sections